<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2017.71001</article-id><article-id pub-id-type="publisher-id">ACM-19878</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20170100000_89704167.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肢端肥大症患者生长激素水平及其与临床资料、生化指标及甲状腺激素水平的关系分析
  Growth Hormone Level in Patients with Acromegaly and Its Relationship with Clinical Data, Biochemical Indexes and Thyroid Hormone Levels
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>鸿悦</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>胡</surname><given-names>玲</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>山西医科大学附属人民医院内分泌科，山西 太原</addr-line></aff><aff id="aff2"><addr-line>山西医科大学，山西 太原 </addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>09</day><month>03</month><year>2017</year></pub-date><volume>07</volume><issue>01</issue><fpage>1</fpage><lpage>5</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨肢端肥大症患者生长激素水平及其与临床资料、生化指标及甲状腺激素水平之间的关系。方法：回顾性分析2012年1月~2016年12月在山西医科大学附属人民医院神经外科就诊65例肢端肥大症患者的一般临床资料、肝肾功能等生化指标及甲状腺功能。结果：肢端肥大症患者生长激素水平与临床资料、肝肾功能无相关性(r = −0.057~−0.104，P均 &gt; 0.05)；与总胆固醇(TC)呈正相关(r = 0.279, P &lt;0.05)，与LDL、HDL、TG无相关性(r = 0.104, 0.185, −0.104, P &gt; 0.05)；与TSH呈负相关(r = −0.402, P &lt; 0.01)；与TT
   <sub>4</sub>水平呈正相关(r = 0.332, P &lt; 0.01)；与
   FT
   <sub style="text-align:justify;white-space:normal;">3</sub>
   、TT
   <sub style="text-align:justify;white-space:normal;">3</sub>
   、FT
   <sub style="text-align:justify;white-space:normal;">4</sub>之间无相关性(r = 0.151, −0.06, 0.243, P &gt; 0.05)。结论：肢端肥大症型垂体腺瘤的血清生长激素水平与肿瘤体积、肝功、肾功无相关性。血脂方面，其与TC水平正相关，与LDL、HDL、TG无相关性。甲状腺激素方面，其与TSH水平呈负相关，与TT
   <sub>4</sub>水平呈正相关，与FT
   <sub>3</sub>、TT
   <sub>3</sub>、FT
   <sub>4</sub>之间无相关性。
    Objective: To explore the growth hormone (GH) level in the patients with acromegaly and its re-lationship with clinical data, biochemical indexes and thyroid hormone levels. Methods: The clinical data, biochemical indicators such as liver and kidney function and thyroid function of 65 acromegaly patients with pituitary adenomas, who visited Shanxi Medical University Affiliated People’s Hospital from January 2012 to December 2016, were analyzed retrospectively. Results: There was no significant correlation among serum GH, clinical data, liver and kidney function in the patients with acromegaly (r = −0.057 - −0.104, P &gt; 0.05). Serum GH has positive correlation with TC (r = 0.279, P &lt; 0.05) and no correlation with LDL, HDL, TG (r = 0.104, 0.185, −0.104, P &gt; 0.05). Serum GH has negative correlation with TSH (r = −0.402, P &lt; 0.01); but positive correlation with TT
   <sub>4</sub> (r = 0.332, P &lt; 0.01) and no correlation with 
   FT
   <sub style="text-align:justify;white-space:normal;">3</sub>
   , TT
   <sub style="text-align:justify;white-space:normal;">3</sub>
   , FT
   <sub style="text-align:justify;white-space:normal;">4</sub> (r = 0.151, −0.06, 0.243, P &gt; 0.05). Conclusions: The serum GH level in the patients with acromegaly is insignificantly related to the adenomas volume, liver function and renal function. In the aspect of blood lipid, , the serum GH level was positively correlated with TC level, and had no correlation with LDL, HDL, TG. In the aspect of thyroid function, the serum GH level was negatively correlated with TSH level and positively correlated with TT
   <sub>4</sub> level, and no correlation with FT
   <sub>3</sub>, TT
   <sub>3</sub>, FT
   <sub>4</sub>. 
  
 
</p></abstract><kwd-group><kwd>肢端肥大症，生长激素，甲状腺激素, Acromegaly</kwd><kwd> Growth Hormone</kwd><kwd> Thyroid Hormone</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>肢端肥大症患者生长激素水平及其 与临床资料、生化指标及甲状腺 激素水平的关系分析<sup> </sup></title><p>于鸿悦<sup>1</sup>，胡玲<sup>2*</sup></p><p><sup>1</sup>山西医科大学，山西 太原</p><p><sup>2</sup>山西医科大学附属人民医院内分泌科，山西 太原</p><disp-formula id="hanspub.19878-formula1"><graphic xlink:href="http://html.hanspub.org/file/1-1570298x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2017年2月25日；录用日期：2017年3月6日；发布日期：2017年3月9日</p><disp-formula id="hanspub.19878-formula2"><graphic xlink:href="http://html.hanspub.org/file/1-1570298x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨肢端肥大症患者生长激素水平及其与临床资料、生化指标及甲状腺激素水平之间的关系。方法：回顾性分析2012年1月~2016年12月在山西医科大学附属人民医院神经外科就诊65例肢端肥大症患者的一般临床资料、肝肾功能等生化指标及甲状腺功能。结果：肢端肥大症患者生长激素水平与临床资料、肝肾功能无相关性(r = −0.057~−0.104，P均 &gt; 0.05)；与总胆固醇(TC)呈正相关(r = 0.279, P &lt;0.05)，与LDL、HDL、TG无相关性(r = 0.104, 0.185, −0.104, P &gt; 0.05)；与TSH呈负相关(r = −0.402, P &lt; 0.01)；与TT<sub>4</sub>水平呈正相关(r = 0.332, P &lt; 0.01)；与FT<sub>3</sub>、TT<sub>3</sub>、FT<sub>4</sub>之间无相关性(r = 0.151, −0.06, 0.243, P &gt; 0.05)。结论：肢端肥大症型垂体腺瘤的血清生长激素水平与肿瘤体积、肝功、肾功无相关性。血脂方面，其与TC水平正相关，与LDL、HDL、TG无相关性。甲状腺激素方面，其与TSH水平呈负相关，与TT<sub>4</sub>水平呈正相关，与FT<sub>3</sub>、TT<sub>3</sub>、FT<sub>4</sub>之间无相关性。</p><p>关键词 :肢端肥大症，生长激素，甲状腺激素</p><disp-formula id="hanspub.19878-formula3"><graphic xlink:href="http://html.hanspub.org/file/1-1570298x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="http://image.hanspub.org:8080\Html/htmlimages\1-2890033x\e70a10f1-7c93-45ea-9603-062237856e4b.png" /><img src="http://image.hanspub.org:8080\Html\htmlimages\1-2890033x\e898c85e-ffc4-45c9-b817-14224a4d6960.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>肢端肥大症是一种起病隐匿的慢性进展性内分泌疾病，95%以上的肢端肥大症患者是由分泌生长激素(growth hormone, GH)的垂体腺瘤所致。长期过度分泌的GH可导致全身软组织、骨和软骨过度增生，引起面容改变、手足肥大、皮肤粗厚、内脏增大以及骨关节病变等。这些代谢紊乱性疾病和并发症严重影响患者的健康和生存质量，导致患者寿命缩短 [<xref ref-type="bibr" rid="hanspub.19878-ref1">1</xref>] 。本研究通过测定肢端肥大症型垂体腺瘤血清GH水平，并分析其与性别、身体质量指数(body mass index, BMI)、生化指标及甲状腺激素水平的相关性，从而为诊治肢端肥大症提供必要的信息。</p></sec><sec id="s4"><title>2. 对象与方法</title><sec id="s4_1"><title>2.1. 研究对象</title><p>收集2012年1月~2016年11月在山西医科大学附属人民医院神经外科经手术和病理证实的65例肢端肥大症患者。其中男性34例，女性31例；平均年龄(45.42 &#177; 12.08)岁(19~72岁)；平均BMI (27.19 &#177; 3.89) kg/m<sup>2</sup> (21.1~37.55 kg/m<sup>2</sup>)。根据生长激素水平是否大于30 ng/ml将生长激素水平分为低生长激素水平组(44例)和高生长激素水平组(17例)。</p></sec><sec id="s4_2"><title>2.2. 方法</title><p>测量所有受试对象身高、体重。所有患者均于入院次日清晨空腹抽取静脉血8 ml，分离血清。用全自动生化分析仪测定肝肾功能、总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)。采用化学发光法测定血清促甲状腺素(TSH)，游离三碘甲状腺原氨酸(FT<sub>3</sub>)，总三碘甲状腺原氨酸(TT<sub>3</sub>)，游离甲状腺素(FT<sub>4</sub>)，总甲状腺素(TT<sub>4</sub>)。</p></sec><sec id="s4_3"><title>2.3. 统计学处理</title><p>采用SPSS 23.0软件进行分析；计量资料以均数&#177;标准差表示，采用t检验。计数资料采用卡方检验。连续性变量相关性分析采用Pearson相关分析。P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 临床资料和生化指标比较</title><p>两组患者年龄、性别、BMI 、最大肿瘤直径、肿瘤体积、肝功、肾功、HDL、TG组间比较无统计学意义。高生长激素水平组LDL、TC水平较低生长激素水平组明显升高，差别有统计学意义(P &lt; 0.05, P &lt; 0.01, 表1)。</p></sec><sec id="s5_2"><title>3.2. 甲状腺激素水平比较</title><p>两组患者TT<sub>3</sub>、FT<sub>3</sub>组间比较无统计学意义。高生长激素水平组TSH水平明显低于低生长激素水平组，差别有统计学意义(P &lt; 0.01，表1)。高生长激素组TT<sub>4</sub>、FT<sub>4</sub>水平明显高于低生长激素水平组，差别有统计学意义(P &lt; 0.01，表1)。</p></sec><sec id="s5_3"><title>3.3. 生长激素与临床资料及生化指标的相关性分析</title><p>对所有肢端肥大症患者进行Pearson相关性分析发现，GH水平与TC水平正相关(r = 0.279, P &lt; 0.05)；与年龄、BMI、最大肿瘤直径、肿瘤体积、AST、ALT、SCr、BUN、LDL、HDL、TG之间无显著相关性(r = −0.057, −0.005, −0.031, 0.042, −0.009, 0.061, −0.013, 0.117, 0.104, 0.185, −0.104, P &gt; 0.05)。</p></sec><sec id="s5_4"><title>3.4. 生长激素与甲状腺激素水平的相关性分析</title><p>肢端肥大症患者GH水平与TSH水平呈负相关(r = −0.402, P &lt; 0.01)；与TT<sub>4</sub>水平呈正相关(r = 0.332, P &lt; 0.01)；与FT<sub>3</sub>、TT<sub>3</sub>、FT<sub>4</sub>之间无显著相关性(r = 0.151, −0.06, 0.243, P &gt; 0.05)。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>GH是促进生长最重要的激素，同时也是机体调节蛋白质、脂肪和碳水化合物代谢的重要激素之一 [<xref ref-type="bibr" rid="hanspub.19878-ref2">2</xref>] 。本研究发现，相比于低生长激素水平组，高生长激素水平组LDL、TC、TT<sub>4</sub>、FT<sub>4</sub>水平明显升高，高</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of 2 groups of biochemical markers and thyroid hormone levels, clinical data of patients with acromegal</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >特征</th><th align="center" valign="middle" >低生长激素水平组</th><th align="center" valign="middle" >高生长激素水平组</th><th align="center" valign="middle" >t/X<sup>2</sup></th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >47 &#177; 10.99</td><td align="center" valign="middle" >40.94 &#177; 14.13</td><td align="center" valign="middle" >1.6</td><td align="center" valign="middle" >0.12</td></tr><tr><td align="center" valign="middle" >性别(男／女)</td><td align="center" valign="middle" >26/18</td><td align="center" valign="middle" >8/9</td><td align="center" valign="middle" >0.72</td><td align="center" valign="middle" >0.39</td></tr><tr><td align="center" valign="middle" >BMI(kg/m<sup>2</sup>)</td><td align="center" valign="middle" >27.44 &#177; 3.71</td><td align="center" valign="middle" >26.5 &#177; 4.43</td><td align="center" valign="middle" >0.86</td><td align="center" valign="middle" >0.39</td></tr><tr><td align="center" valign="middle" >最大肿瘤直径(mm)</td><td align="center" valign="middle" >18.48 &#177; 6.9</td><td align="center" valign="middle" >19.24 &#177; 6.87</td><td align="center" valign="middle" >-0.39</td><td align="center" valign="middle" >0.7</td></tr><tr><td align="center" valign="middle" >肿瘤体积(mm<sup>3</sup>)</td><td align="center" valign="middle" >26.13 &#177; 33.75</td><td align="center" valign="middle" >28.22 &#177; 30.66</td><td align="center" valign="middle" >-0.22</td><td align="center" valign="middle" >0.82</td></tr><tr><td align="center" valign="middle" >AST(IU/L)</td><td align="center" valign="middle" >19.18 &#177; 9.65</td><td align="center" valign="middle" >17.05 &#177; 4.9</td><td align="center" valign="middle" >0.87</td><td align="center" valign="middle" >0.39</td></tr><tr><td align="center" valign="middle" >ALT(IU/L)</td><td align="center" valign="middle" >22.51 &#177; 19.9</td><td align="center" valign="middle" >21.34 &#177; 11.73</td><td align="center" valign="middle" >0.23</td><td align="center" valign="middle" >0.82</td></tr><tr><td align="center" valign="middle" >SCr(umol/L)</td><td align="center" valign="middle" >57.11 &#177; 15.92</td><td align="center" valign="middle" >61.63 &#177; 12.41</td><td align="center" valign="middle" >-1.06</td><td align="center" valign="middle" >0.29</td></tr><tr><td align="center" valign="middle" >BUN(mmol/L)</td><td align="center" valign="middle" >4.12 &#177; 0.88</td><td align="center" valign="middle" >4.40 &#177; 1.23</td><td align="center" valign="middle" >-0.98</td><td align="center" valign="middle" >0.33</td></tr><tr><td align="center" valign="middle" >LDL(mmol/L)</td><td align="center" valign="middle" >2.21 &#177; 0.53</td><td align="center" valign="middle" >2.57 &#177; 0.56</td><td align="center" valign="middle" >-2.43</td><td align="center" valign="middle" >0.02</td></tr><tr><td align="center" valign="middle" >HDL(mmol/L)</td><td align="center" valign="middle" >1.06 &#177; 0.24</td><td align="center" valign="middle" >1.02 &#177; 0.25</td><td align="center" valign="middle" >0.61</td><td align="center" valign="middle" >0.54</td></tr><tr><td align="center" valign="middle" >TG(mmol/L)</td><td align="center" valign="middle" >1.66 &#177; 0.67</td><td align="center" valign="middle" >1.66 &#177; 1.29</td><td align="center" valign="middle" >-0.01</td><td align="center" valign="middle" >0.99</td></tr><tr><td align="center" valign="middle" >TC(mmol/L)</td><td align="center" valign="middle" >3.71 &#177; 0.57</td><td align="center" valign="middle" >4.45 &#177; 0.66</td><td align="center" valign="middle" >-4.41</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >TSH(uIU/mL)</td><td align="center" valign="middle" >1.6 &#177; 0.79</td><td align="center" valign="middle" >0.74 &#177; 0.22</td><td align="center" valign="middle" >6.98</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >TT<sub>4</sub>(pmol/L)</td><td align="center" valign="middle" >109.92 &#177; 18.36</td><td align="center" valign="middle" >124.29 &#177; 11.55</td><td align="center" valign="middle" >-3.73</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >TT<sub>3</sub>(nmol/L)</td><td align="center" valign="middle" >1.86 &#177; 0.26</td><td align="center" valign="middle" >1.74 &#177; 0.22</td><td align="center" valign="middle" >1.68</td><td align="center" valign="middle" >0.1</td></tr><tr><td align="center" valign="middle" >FT<sub>4</sub>(pmol/L)</td><td align="center" valign="middle" >10.84 &#177; 1.96</td><td align="center" valign="middle" >12.11 &#177; 1.37</td><td align="center" valign="middle" >-2.91</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >FT<sub>3</sub>(pmol/L)</td><td align="center" valign="middle" >5.05 &#177; 0.54</td><td align="center" valign="middle" >5.12 &#177; 0.56</td><td align="center" valign="middle" >-0.47</td><td align="center" valign="middle" >0.65</td></tr></tbody></table></table-wrap><p>表1. 2组肢端肥大症患者临床资料、生化指标及甲状腺激素水平比较</p><p>生长激素水平组TSH水平明显降低。肢端肥大症患者生长激素水平与TC水平正相关，与年龄、BMI、最大肿瘤直径、肿瘤体积、肝功、肾功、LDL、HDL、TG之间无显著相关性。与TSH水平呈负相关，与TT<sub>4</sub>水平呈正相关，与FT<sub>3</sub>、TT<sub>3</sub>、FT<sub>4</sub>之间无明显相关性。</p><p>目前，肢端肥大症型垂体腺瘤患者的基础GH值与瘤体体积是否具有相关性仍有争议。Ryosuke Mori等 [<xref ref-type="bibr" rid="hanspub.19878-ref3">3</xref>] 对242例肢端肥大症患者研究发现，GH型和GH-PRL型垂体腺瘤的肿瘤体积与其基础血清GH水平显著相关(r = 0.777, P &lt; 0.001; r = 0.931, P &lt; 0.001)。而孔令胜等 [<xref ref-type="bibr" rid="hanspub.19878-ref4">4</xref>] 报道肢端肥大症型垂体腺瘤瘤体大小与基础血清GH值无明显相关性，我们的研究与其报道一致，这可能与瘤体内GH含量不一致或血液循环内GH含量不同于瘤体内GH含量有关。因此，肢端肥大症患者血清GH水平的高低并不能代表其瘤体体积的大小，目前尚不能依据血清GH水平来推断肿瘤体积的大小。</p><p>肢端肥大症患者血脂紊乱的发生率很高，而其脂代谢的特点尚无一致性，但多数研究提出，肢端肥大症患者的血甘油三酯水平高于正常人群，机制并不是很清楚 [<xref ref-type="bibr" rid="hanspub.19878-ref5">5</xref>] 。本研究中，尽管两组血甘油三酯水平并无显著差异，但均高于正常参考范围。而高生长激素水平组低密度脂蛋白胆固醇和总胆固醇水平明显高于低生长激素水平组，这可能与过量的GH可直接导致脂蛋白脂肪酶(LPL)活性下降，并增加肝脏低密度脂蛋白－胆固醇(LDL-C)表达有关 [<xref ref-type="bibr" rid="hanspub.19878-ref6">6</xref>] 。通过相关分析进一步证实血清GH与总胆固醇成正相关，这与Jaskula M等 [<xref ref-type="bibr" rid="hanspub.19878-ref7">7</xref>] 的研究结果一致。脂代谢异常既影响肢端肥大症及其并发症的病理生理过程，又是增加心血管疾病和糖代谢紊乱的重要因素，因此，针对肢端肥大症患者，应重视早期诊断和筛查，以使患者尽早获得干预，控制代谢紊乱，延缓疾病进展，从而防治心脑血管终点事件的发生。</p><p>GH与TSH之间的负相关可能与肢端肥大症患者中促甲状腺激素释放激素(TRH)的合成和释放 [<xref ref-type="bibr" rid="hanspub.19878-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.19878-ref9">9</xref>] 。我们研究发现，肢端肥大症患者的GH水平与TSH呈负相关，与Ferdinand Roelfsema等 [<xref ref-type="bibr" rid="hanspub.19878-ref10">10</xref>] 研究结果一致。本研究统计数据显示，两组间TT<sub>3</sub>、FT<sub>3</sub>无明显差异，高生长激素组较低生长激素水平组TT<sub>4</sub>、FT<sub>4</sub>水平高。这可能与TSH的生物活性增高或是甲状腺的敏感性因交感输入的减少而反馈性增强有关 [<xref ref-type="bibr" rid="hanspub.19878-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.19878-ref11">11</xref>] 。本研究还发现GH水平与TT<sub>4</sub>水平呈正相关，这说明甲状腺激素的分泌不仅受TSH调节，也受生长激素调节。</p><p>总之，肢端肥大症型垂体腺瘤的血清GH水平与肿瘤体积、肝功、肾功无明显相关性。血脂方面，血清GH水平与TC水平正相关。甲状腺激素方面，血清GH水平与TSH水平呈负相关，与TT<sub>4</sub>水平呈正相关，与FT<sub>3</sub>、TT<sub>3</sub>、FT<sub>4</sub>之间无明显相关性。</p></sec><sec id="s7"><title>文章引用</title><p>于鸿悦,胡 玲. 肢端肥大症患者生长激素水平及其与临床资料、生化指标及甲状腺激素水平的关系分析 Growth Hormone Level in Patients with Acromegaly and Its Relationship with Clinical Data, Biochemical Indexes and Thyroid Hormone Levels[J]. 临床医学进展, 2017, 07(01): 1-5. http://dx.doi.org/10.12677/ACM.2017.71001</p></sec><sec id="s8"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.19878-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会内分泌学分会, 中华医学会神经外科学分会, 中国垂体腺瘤协助组. 中国肢端肥大症诊治指南(2013年版)[J]. 中华医学杂志, 2013, 93(27): 2106-2111.</mixed-citation></ref><ref id="hanspub.19878-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">吴勤勇, 朱惠娟, 顾锋, 等. 肢端肥大症患者垂体生长激素瘤切除术后身体组分的改变[J]. 基础医学与临床, 2010, 30(4): 411-414.</mixed-citation></ref><ref id="hanspub.19878-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Mori, R., Inoshita, N., Takahashi-Fujigasaki, J., et al. (2013) Clinicopathological Features of Growth Hormone-Producing Pituitary Adenomas in 242 Acromegaly Patients: Classification According to Hormone Production and Cytokeratin Distribution. ISRN Endocrinology, 2013, Article ID: 723432. &lt;br&gt;https://doi.org/10.1155/2013/723432</mixed-citation></ref><ref id="hanspub.19878-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">孔令胜, 姚维成, 栗世方, 贺昭忠, 成磊. 肢端肥大症型垂体腺瘤MRI特点及其与血清GH水平, 肿瘤GH表达水平的关系分析[J]. 中国临床神经外科杂志, 2014, 19(9): 516-518.</mixed-citation></ref><ref id="hanspub.19878-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Medić-Stojanoska, M. and Pletikosić, I. (2009) Disturbances of Lipid and Lipoprotein Metabolism in Hypeprolactinemia and Acromegaly. Medicinski Pregled, 62, 91-94.</mixed-citation></ref><ref id="hanspub.19878-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">梁丽, 李成江. 肢端肥大症11例并发症临床分析[J]. 中国实用内科杂志, 2005, 25(10): 928-929.</mixed-citation></ref><ref id="hanspub.19878-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Jaskula, M., Wasko, R., Komarowska, H., Dziubandowska, A. and Sowinski, J. (2009) Serum Ghrelin Levels and Disturbances of the Lipid Profile in Patients with Acromegaly. Neuroendo-crinology Letters, 30, 245-255.</mixed-citation></ref><ref id="hanspub.19878-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Gasperi, M., Martino, E., Manetti, L., et al. (2002) Prevalence of Thyroid Diseases in Patients with Acromegaly: Results of an Italian Multicenter Study. Journal of Endocrinological Investigation, 25, 240-245.  
&lt;br&gt;https://doi.org/10.1007/BF03343997</mixed-citation></ref><ref id="hanspub.19878-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Herrmann, B.L., Baumann, H., Janssen, O.E., Görges, R., Schmid, K.W. and Mann, K. (2004) Impact of Disease Activity on Thyroid Diseases in Patients with Acromegaly: Basal Evaluation and Fol-low-Up. Experimental and Clinical Endocrinology &amp; Diabetes, 112, 225-230. &lt;br&gt;https://doi.org/10.1055/s-2004-817967</mixed-citation></ref><ref id="hanspub.19878-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Roelfsema, F., Biermasz, N.R., Frolich, M., Keenan, D.M., Veldhuis, J.D. and Romijn, J.A. (2009) Diminished and Irregular Thyrotropin Secretion with Preserved Diurnal Rhythm in Patients with Active Acromegaly. The Journal of Clinical Endocrinology &amp; Metabolism, 94, 1945-1950. &lt;br&gt;https://doi.org/10.1210/jc.2009-0174</mixed-citation></ref><ref id="hanspub.19878-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kalsbeek, A., Fliers, E., Franke, A.N., Wortel, J. and Buijs, R.M. (2000) Functional Connections between the Suprachiasmatic Nucleus and the Thyroid Gland as Revealed by Lesioning and Viral Tracing Techniques in the Rat. Endocrinology, 141, 3832-3841. &lt;br&gt;https://doi.org/10.1210/endo.141.10.7709</mixed-citation></ref></ref-list></back></article>